Colorectal Cancer

Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.

The WEE1 inhibitor adavosertib improved progression-free survival with a tolerable safety profile compared with active monitoring in patients with RAS/TP53-mutated metastatic colorectal cancer.

Shikha Jain, MD, FACP, discusses the need to enroll heterogenous patient populations to clinical trials in colorectal cancer.

Georges Azzi, MD, discusses the utility of the Signatera circulating tumor DNA assay as a preferred test in colorectal cancer (CRC).

Kanwal Raghav, MBBS, MD, discusses treatment considerations in metastatic colorectal cancer.

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

Syma Iqbal, MD, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).

Kanwal Raghav, MBBS, MD, discusses the safety profiles of regorafenib and trifluridine/tipiracil, and selecting between the agents for the treatment of patients with colorectal cancer.

Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.

Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.

The FDA has granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer.

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

Kristen K. Ciombor, MD, MSCI, discusses the use of anti-EGFR therapy for the frontline treatment of patients with metastatic colorectal cancer.

Chemotherapy has demonstrated mixed findings in patients with resectable colorectal hepatic metastases, and long-term data suggest incorporating it into treatment algorithms have little impact on overall survival.

The combination of nivolumab and low-dose ipilimumab resulted in a deep and durable clinical benefit when used in the first-line treatment of patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

Joleen M. Hubbard, MD, discusses minimal residual disease assessment to inform treatment decisions in patients with resected metastatic colorectal cancer.

Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factors to consider during surgical and systemic treatment decisions, and the importance of multidisciplinary care in this patient population.

The randomized FORTE/NRG-CC005 trial, which is evaluating the frequency of surveillance colonoscopy in individuals with a first-time presentation and removal of 1 to 2 small, benign polyps, has been launched.

The frontline combination of trifluridine/tipiracil and bevacizumab was not found to result in a significant improvement in progression-free survival over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial.

Jared Weiss, MD, discusses the rationale for the phase 1/2 KRYSTAL-1 trial in patients with KRAS G12C–mutated colorectal cancer.

Mary F. Mulcahy, MD, discusses the key takeaways from the ongoing EPOCH trial in patients with colorectal cancer and liver metastases.